Most recently known for his lucrative short position in Lehman Brothers, David Einhorn has made a name through his hedge fund Greenlight Capital.
Founded in 1996 with only $900K under management, Greenlight is perceived as one of the most respected value-oriented investment firms in the industry. Not to mention that Einhorn once finished in eighteenth place at the World Series of poker.
Yet, what is most impressive about this firm is its great ability to make significantly profitable short sale trades. "His shorts on Conseco, CompuCredit, Sirrom Capital, and Resource America -- some of the more spectacular corporate flameouts of the late nineties and early aughts -- each returned more than 80 percent," wrote New York Magazine, in a recent interview with the hedge fund superstar.
With that said, we will only focus on the long positions of this firm.
According to Greenlight's recent 13F SEC filing, the fund holds approximately $5B in equities traded in the big three (AMEX, NASDAQ, and NYSE), which implies a 7.3% increase from the previous filing.
Its biggest holding at the end of the previous quarter is Pfizer
List of Greenlight's Top 5 Holdings:
1. Pfizer: Drug Manufacturer. Market cap of $158.89B. Shares held as of Dec. 31, 2010: 23,154,098 vs. 24,954,098 shares held as of March 31, 2011. This position changed by 7.77% and it represents 10.16% of the portfolio as of the most recent filing.
2. Apple
3. CIT Group
4. CareFusion
5. Sprint Nextel
List of the Top 5 Ownership Increases:
1. BioFuel Energy (BIOF): Specialty Chemicals Industry. Market cap of $17.79M. Shares held as of Dec. 31, 2010: 7,542,104 vs. 27,168,879 shares held as of March 31, 2011. This position changed by 260.23% and it represents 0.45% of the portfolio as of the most recent filing.
2. The Travelers Companies
3. Becton, Dickinson and Company
4. Microsoft
5. Pfizer: Drug Manufacturer. Market cap of $158.89B. Shares held as of Dec. 31, 2010: 23,154,098 vs. 24,954,098 shares held as of March 31, 2011. This position changed by 7.77% and it represents 10.16% of the portfolio as of the most recent filing.
Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the stocks mentioned above. Analyst ratings sourced from Zacks Investment Research.
Kapitall's Eben Esterhuizen does not own any of the shares mentioned above.